期刊文献+

氨溴索对罗红霉素大鼠体内药动学的影响

Effect of aebroxol on The Pharmacokientice of Roxithromycin in Rats
下载PDF
导出
摘要 目的:研究氨溴索(Amb)对罗红霉素(RM)大鼠体内药代动力学的影响,探讨药物间的相互作用及联合用药的合理性。方法:72只SD大鼠随机分为4组,给药前禁食12h。对照组的大鼠单独予RM;实验组Ⅰ、Ⅱ、Ⅲ分别预先给药2.7mg.kg-1、5.4mg.kg-1、10.8mg.kg-1剂量的Amb,tid×6d,于第7d给药Amb+RM。给药后经眼眶静脉丛采集血样,样品处理后采用反相HPLC-UV检测法测定不同时间RM的血药浓度,采用DAS2.1.1统计软件求算该药单用及联合用药后的药动学参数。结果:采用随机区组的方差分析进行统计学处理,实验组与对照组各组间RM的主要药动学参数Tmax、T1/2z、Cmax、Vz、CLz、AUC0~t、AUC0~∞差异均无统计学意义(p>0.05)。结论:Amb与RM联合使用时,Amb对RM大鼠体内药代动力学过程无明显影响,二者联合使用安全,本结果为临床安全有效地使用Amb和RM提供了一定的实验依据。 OBJECTIVE:In order to evaluate the interactions and rationality of drug combination in clinic between Amb and RM,the influences of Amb on the pharmacokinetic parameters of RM in rats were investigated in this research. METHOD:72 SD rats were randomly divided into 4 groups.The RM was given to the control group while Amb which were at doses of 2.7mg· kg-1,5.4 mg·kg-1,10.8 mg·kg-1 were given to experimental group Ⅰ,Ⅱ and Ⅲfor 6 days,and given together with RM at the seventh day respectively.Blood samples were collected by orbital plexus.The RM concentrations in the plasma were determinated by HPLC-UV,and the pharmacokinetic parameters of RM were calculated by DAS 2.1.1. RESULTS:The results showed that there were no significant differences on the main pharmacokinetic parameters of RM such as Tmax,T1/2z,Cmax,Vz,CLz,AUC0~t and AUC0~∞ between the experimental groups and the control group(p〉0.05). CONCLUSION:The Amb did not have significant influences on the pharmacokinetic of RM in rats.It is safe to use the combination of the two drugs and there is no need to adjust the dosage of RM.This study provided a certain experimental evidence for clinical use of RM when co-administrated with Amb.
作者 张磊
出处 《九江学院学报(自然科学版)》 CAS 2011年第2期47-50,共4页 Journal of Jiujiang University:Natural Science Edition
关键词 罗红霉素 氨溴索 高效液相色谱法 药代动力学 Roxithromycin Ambroxol HPLC pharmacokinetics
  • 相关文献

参考文献7

二级参考文献35

  • 1张淑秋,张丽锋,邢杰,钟大放.罗红霉素在犬体内的代谢转化[J].药学学报,2003,38(5):374-379. 被引量:3
  • 2哈力,哈娜,胡宝荣.塞来昔布安全性与耐受性评价[J].中国药师,2005,8(4):323-324. 被引量:6
  • 3法国OVP维德.维德临床用药年鉴[M].北京:中信出版社,1999.223.
  • 4李家泰.治疗呼吸系统疾病的药物[A]..临床药理学:第2版[C].北京:人民卫生出版社,1998.1125.
  • 5[5]Tang C,Shou M,Mei Q,et al.Major role of human liver microsomal cytochrome P450 2C9 (CYP2C9)in the oxidative metabolism of celecoxib,a novel cyclooxygenase-Ⅱ inhibitor[J].J Pharmacol Exp Ther,2000,293 (2):453.
  • 6[6]Yamazaki H,Hiroki S,Urano T,et al.Effects of rroxithromycin,erythromycin and troleandomycin on their N-demethylation by rat and human cytochrome P450 enzymes[J].Xenobiotica,1996,26:1143.
  • 7Koyama M, Tateno M, Shirotsuka M. Yamamoto M,Hirayama M, Saitoh K. et al. Absorption, metabolism and excretion of RU 28965 in humans. Chemotherapy 1988; 36:164 - 83.
  • 8Jarukaamjom K, Thalhammer T, Gollackner B, Pittenauer E,Jaeger W. Metabolism of roxithromycin in the isolated perfused rat liver. J Pharm Pharmacol 1998;50:515-9.
  • 9Yamazaki H, Shimada T. Formation in vitro of an inhibitory cytochrome P450 × Fe^2+ -metabolite complex with roxithro-mycin and its decladinosyl, O-dealkyl and N-delnethyl meta-bolites in rat liver microsomes. Xenobiotica 1998; 28:995 -1004.
  • 10Markham A, Faulds D. Roxithromycin: an update of its antmicrobial accivity, pharmacokinetic properties and therapeutic use. Drugs 1994; 48: 297 - 326.

共引文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部